ATE304011T1 - Hydantoin-enthaltende glucokinase aktivatoren - Google Patents

Hydantoin-enthaltende glucokinase aktivatoren

Info

Publication number
ATE304011T1
ATE304011T1 AT01925563T AT01925563T ATE304011T1 AT E304011 T1 ATE304011 T1 AT E304011T1 AT 01925563 T AT01925563 T AT 01925563T AT 01925563 T AT01925563 T AT 01925563T AT E304011 T1 ATE304011 T1 AT E304011T1
Authority
AT
Austria
Prior art keywords
glucocinase
activators
hydantoin containing
hydantoin
glucocinase activators
Prior art date
Application number
AT01925563T
Other languages
English (en)
Inventor
Robert Alan Goodnow Jr
Kang Le
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE304011T1 publication Critical patent/ATE304011T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
AT01925563T 2000-05-03 2001-04-23 Hydantoin-enthaltende glucokinase aktivatoren ATE304011T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20149800P 2000-05-03 2000-05-03
PCT/EP2001/004555 WO2001083478A2 (en) 2000-05-03 2001-04-23 Hydantoin-containing glucokinase activators

Publications (1)

Publication Number Publication Date
ATE304011T1 true ATE304011T1 (de) 2005-09-15

Family

ID=22746054

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01925563T ATE304011T1 (de) 2000-05-03 2001-04-23 Hydantoin-enthaltende glucokinase aktivatoren

Country Status (20)

Country Link
US (2) US6583288B2 (de)
EP (1) EP1280801B1 (de)
JP (1) JP3842131B2 (de)
KR (1) KR100505312B1 (de)
CN (1) CN1209361C (de)
AR (1) AR034253A1 (de)
AT (1) ATE304011T1 (de)
AU (2) AU5227001A (de)
BR (1) BR0110492A (de)
CA (1) CA2407428C (de)
DE (1) DE60113247T2 (de)
DK (1) DK1280801T3 (de)
EC (1) ECSP014055A (de)
ES (1) ES2248309T3 (de)
MX (1) MXPA02010746A (de)
PE (1) PE20011313A1 (de)
PT (1) PT1280801E (de)
UY (1) UY26689A1 (de)
WO (1) WO2001083478A2 (de)
ZA (1) ZA200208370B (de)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE304011T1 (de) * 2000-05-03 2005-09-15 Hoffmann La Roche Hydantoin-enthaltende glucokinase aktivatoren
US6482951B2 (en) 2000-12-13 2002-11-19 Hoffmann-La Roche Inc. Isoindolin-1-one glucokinase activators
SE0102299D0 (sv) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
CZ2004747A3 (cs) 2001-12-21 2004-11-10 Novo Nordisk A/S Deriváty amidů jako GK aktivátory
MXPA05000130A (es) 2002-06-27 2005-02-17 Novo Nordisk As Derivados de aril-carbonilo como agentes terapeuticos.
RU2340605C2 (ru) 2002-06-27 2008-12-10 Ново Нордиск А/С Арилкарбонильные производные в качестве терапевтических средств
NZ539013A (en) 2002-10-03 2007-05-31 Novartis Ag Substituted (thiazol-2-yl) -amide or sulfonamide as glycokinase activators useful in the treatment of type 2 diabetes
GB0226931D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
US7132425B2 (en) * 2002-12-12 2006-11-07 Hoffmann-La Roche Inc. 5-substituted-six-membered heteroaromatic glucokinase activators
PL378117A1 (pl) 2003-02-11 2006-03-06 Prosidion Limited Tricyklopodstawione związki amidowe
JP4621198B2 (ja) * 2003-02-11 2011-01-26 プロシディオン・リミテッド トリ（シクロ）置換アミドグルコキナーゼ活性化化合物
CN1910166B (zh) * 2004-01-06 2012-01-04 诺和诺德公司 杂芳基脲及其作为葡糖激酶活化剂的用途
WO2005066145A1 (en) 2004-01-06 2005-07-21 Novo Nordisk A/S Heteroaryl-ureas and their use as glucokinase activators
AU2005229416B2 (en) 2004-04-02 2009-03-26 Novartis Ag Sulfonamide-thiazolpyridine derivatives as glucokinase activators useful the treatment of type 2 diabetes
EP1737870A1 (de) 2004-04-02 2007-01-03 Novartis AG Thiazolopyridinderivate, pharmazeutische zusammensetzungen, die diese enthalten, und verfahren zur behandlung von durch glucokinase vermittelten leiden
AU2005274390B2 (en) 2004-08-17 2012-01-19 F. Hoffmann-La Roche Ag Substituted hydantoins
US7696192B2 (en) 2004-09-09 2010-04-13 Merck Sharp & Dohme Corp. Tricyclic anilide spirolactam CGRP receptor antagonists
US8003792B2 (en) 2004-09-13 2011-08-23 Merck Sharp & Dohme Corp. Bicyclic anilide spirolactam CGRP receptor antagonists
US7390798B2 (en) * 2004-09-13 2008-06-24 Merck & Co., Inc. Carboxamide spirolactam CGRP receptor antagonists
TW200621766A (en) 2004-09-17 2006-07-01 Hoffmann La Roche Substituted hydantoins
WO2007006760A1 (en) 2005-07-08 2007-01-18 Novo Nordisk A/S Dicycloalkyl urea glucokinase activators
EP1910317B1 (de) 2005-07-20 2013-07-03 Eli Lilly And Company 1-amino-verbundene verbindungen
JP2007063225A (ja) 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
NZ566877A (en) 2005-09-29 2010-05-28 Sanofi Aventis Phenyl-1,2,4-oxadiazolone derivatives, processes for their preparation and their use as pharmaceuticals
GT200600429A (es) 2005-09-30 2007-04-30 Compuestos organicos
GT200600428A (es) 2005-09-30 2007-05-21 Compuestos organicos
WO2007123581A1 (en) 2005-11-17 2007-11-01 Eli Lilly And Company Glucagon receptor antagonists, preparation and therapeutic uses
EP1948614A2 (de) * 2005-11-18 2008-07-30 Takeda San Diego, Inc. Glucokinaseaktivatoren
FR2894962B1 (fr) * 2005-12-20 2008-03-14 Pharmamens Sarl Hydantoines a action insulinotropique
US7612212B2 (en) 2006-02-22 2009-11-03 Hoffmann-La Roche Inc. Substituted hydantoins
JP5302012B2 (ja) * 2006-03-08 2013-10-02 タケダ カリフォルニア インコーポレイテッド グルコキナーゼ活性剤
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
WO2007143434A2 (en) 2006-05-31 2007-12-13 Takeda San Diego, Inc. Indazole and isoindole derivatives as glucokinase activating agents
US20080107725A1 (en) * 2006-10-13 2008-05-08 Albano Antonio A Pharmaceutical Solid Dosage Forms Comprising Amorphous Compounds Micro-Embedded in Ionic Water-Insoluble Polymers
WO2008079787A2 (en) * 2006-12-20 2008-07-03 Takeda San Diego, Inc. Glucokinase activators
TW200831081A (en) 2006-12-25 2008-08-01 Kyorin Seiyaku Kk Glucokinase activator
MX2009009525A (es) * 2007-03-07 2009-09-16 Kyorin Seiyaku Kk Activador de glucocinasa.
CA2680307A1 (en) * 2007-03-12 2008-09-18 Merck & Co., Inc. Monocyclic anilide spirolactam cgrp receptor antagonists
WO2008116107A2 (en) 2007-03-21 2008-09-25 Takeda San Diego, Inc. Piperazine derivatives as glucokinase activators
KR101147583B1 (ko) * 2007-08-16 2012-05-21 에프. 호프만-라 로슈 아게 치환 히단토인
CN101896469A (zh) 2007-12-20 2010-11-24 霍夫曼-拉罗奇有限公司 作为mek激酶抑制剂的取代的乙内酰脲类化合物
US8258134B2 (en) * 2008-04-16 2012-09-04 Hoffmann-La Roche Inc. Pyridazinone glucokinase activators
KR101608259B1 (ko) 2008-04-28 2016-04-01 교린 세이야꾸 가부시키 가이샤 시클로펜틸아크릴산아미드 유도체
UY31830A (es) 2008-05-16 2010-01-05 Takeda Pharmaceutical Activadores de glucoquinasa
US8450494B2 (en) 2009-06-22 2013-05-28 Cadila Healthcare Limited Disubstituted benzamide derivatives as glucokinase (GK) activators
JP2013500961A (ja) 2009-07-31 2013-01-10 カディラ ヘルスケア リミテッド グルコキナーゼ（ｇｋ）アクチベーターとしての置換ベンズアミド誘導体
JP5909482B2 (ja) 2010-03-31 2016-04-26 ザ スクリプス リサーチ インスティテュート 細胞の再プログラム
ES2671881B1 (es) * 2016-11-11 2019-03-25 Consejo Superior Investigacion Procedimiento de obtencion de polimeros con grupos isocianato
CN112040945A (zh) 2018-06-12 2020-12-04 Vtv治疗有限责任公司 葡萄糖激酶激活剂与胰岛素或胰岛素类似物组合的治疗用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5202339A (en) * 1987-08-28 1993-04-13 Mochida Pharmaceutical Co., Ltd. Hydantoin derivatives
US6320050B1 (en) * 1999-03-29 2001-11-20 Hoffmann-La Roche Inc. Heteroaromatic glucokinase activators
ATE304011T1 (de) * 2000-05-03 2005-09-15 Hoffmann La Roche Hydantoin-enthaltende glucokinase aktivatoren

Also Published As

Publication number Publication date
EP1280801A2 (de) 2003-02-05
JP2003531905A (ja) 2003-10-28
CN1427838A (zh) 2003-07-02
UY26689A1 (es) 2001-11-30
US6784298B2 (en) 2004-08-31
AU2001252270B2 (en) 2005-12-15
MXPA02010746A (es) 2003-03-10
CA2407428C (en) 2010-02-02
KR100505312B1 (ko) 2005-08-04
EP1280801B1 (de) 2005-09-07
DK1280801T3 (da) 2006-01-23
CA2407428A1 (en) 2001-11-08
BR0110492A (pt) 2003-04-08
ES2248309T3 (es) 2006-03-16
PT1280801E (pt) 2005-11-30
JP3842131B2 (ja) 2006-11-08
DE60113247D1 (de) 2005-10-13
ECSP014055A (es) 2002-01-25
US20030225286A1 (en) 2003-12-04
ZA200208370B (en) 2004-01-26
WO2001083478A3 (en) 2002-05-16
US20010056191A1 (en) 2001-12-27
PE20011313A1 (es) 2001-12-28
AR034253A1 (es) 2004-02-18
DE60113247T2 (de) 2006-06-22
WO2001083478A2 (en) 2001-11-08
AU5227001A (en) 2001-11-12
US6583288B2 (en) 2003-06-24
CN1209361C (zh) 2005-07-06
KR20020093120A (ko) 2002-12-12

Similar Documents

Publication Publication Date Title
ATE304011T1 (de) Hydantoin-enthaltende glucokinase aktivatoren
DK1169312T3 (da) Glucokinaseaktivatorer
DK1242397T3 (da) Trans-olefiniske glucokinaseaktivatorer
DE60134470D1 (de) Para-amin substituierte phenylamid glukokinase activatoren
ATE297921T1 (de) Tetrazolylphenyl-acetamide als glukokinaseaktivatoren
AR028253A1 (es) Inhibidores de la glucogeno fosforilasa
NO20030472D0 (no) Imidazolderivater
DK1568367T5 (da) Glucokinase påvirkende forbindelser
DE60042550D1 (de) Mutierte varianten des insulin-ähnlichen wachstumsfaktor i (igf-i)
ATE360620T1 (de) Imidazolderivate
DE60131992D1 (de) Pfropfcopolymere enthaltende klebstoffe
DE50009640D1 (de) Drehmaschine
ATE388040T1 (de) Träger
DE50011953D1 (de) Bohrwerkzeug
NO20025659L (no) Heterocykliske forbindelser
DE50113112D1 (de) Schaltungsanordnung
DE50102328D1 (de) Feuchttücher (i)
DE50011494D1 (de) Bohrwerkzeug
FI20001260A (fi) Kontti
DE50104260D1 (de) Behälter
DE50115426D1 (de) Schaltungsanordnung
FI20001704A0 (fi) Kontti
DK1282612T3 (da) Heteroaromatiske alkylphenyl-glucokinaseaktivatorer
SE0003059D0 (sv) Bärare
ES1045752Y (es) Envase contenedor

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1280801

Country of ref document: EP

REN Ceased due to non-payment of the annual fee